Arvinas, Inc. (ARVN)
NASDAQ: ARVN · IEX Real-Time Price · USD
29.65
+0.13 (0.44%)
At close: Jul 26, 2024, 4:00 PM
29.96
+0.31 (1.05%)
After-hours: Jul 26, 2024, 5:31 PM EDT
Arvinas Revenue
Arvinas had revenue of $25.30M in the quarter ending March 31, 2024, a decrease of -22.15%. This brings the company's revenue in the last twelve months to $71.30M, down -48.11% year-over-year. In the year 2023, Arvinas had annual revenue of $78.50M, down -40.26%.
Revenue (ttm)
$71.30M
Revenue Growth
-48.11%
P/S Ratio
28.55
Revenue / Employee
$160,225
Employees
445
Market Cap
2.03B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BrightSpring Health Services | 9.37B |
Premier | 1.34B |
National HealthCare | 1.17B |
LifeStance Health Group | 1.10B |
NovoCure | 525.66M |
Catalyst Pharmaceuticals | 411.35M |
STAAR Surgical Company | 326.24M |
LeMaitre Vascular | 199.89M |
ARVN News
- 4 weeks ago - Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer - GlobeNewsWire
- 5 weeks ago - Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2 - GlobeNewsWire
- 5 weeks ago - Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D. - GlobeNewsWire
- 7 weeks ago - Arvinas to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress - GlobeNewsWire
- 2 months ago - Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) - GlobeNewsWire
- 2 months ago - Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress - GlobeNewsWire
- 2 months ago - Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire